

Table 15.9
Immunosuppression Use for Maintenance by Regimen
Two Years Following Transplantation, 1998 to 2005
Recipients with Pancreas After Kidney (PAK) Transplants

	Transplant Year							
	1998	1999	2000	2001	2002	2003	2004	2005
Transplants	156	220	304	305	375	344	420	343
Functioning Graft at 2 Years PostTx	103	145	195	223	253	220	280	225
With Maintenance Use Recorded at 2 Years PostTx	102	138	185	217	250	216	273	195
CyA	1.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
Tac	0.0%	0.0%	0.0%	0.9%	1.2%	1.9%	3.7%	3.1%
--- + MMF/MPA	0.0%	0.0%	0.0%	0.9%	0.8%	2.8%	2.6%	0.0%
CyA + MMF/MPA	0.0%	0.0%	0.0%	1.4%	1.2%	1.4%	1.1%	1.0%
Tac + MMF/MPA	2.9%	3.6%	4.9%	6.5%	4.8%	9.3%	13.6%	16.9%
CyA + OtherAntimet	0.0%	0.0%	0.0%	0.0%	0.0%	0.5%	0.0%	0.0%
Tac + OtherAntimet	0.0%	0.7%	0.0%	0.0%	0.0%	0.5%	0.0%	0.5%
--- + Siro/Evero	0.0%	0.0%	0.0%	0.5%	0.0%	0.9%	0.0%	0.0%
CyA + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.4%	0.0%
Tac + Siro/Evero	0.0%	0.0%	1.6%	6.9%	5.6%	6.0%	8.1%	5.1%
--- + MMF/MPA + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.0%	0.5%	0.4%	1.5%
Tac + MMF/MPA + Siro/Evero	0.0%	0.0%	0.0%	0.0%	0.0%	1.9%	0.4%	2.1%
--- + Steroids	0.0%	0.0%	0.0%	1.4%	0.0%	0.0%	0.0%	1.0%
CyA + Steroids	1.0%	0.0%	1.6%	0.9%	0.4%	0.9%	0.0%	0.0%
Tac + Steroids	2.0%	5.1%	6.5%	3.7%	4.4%	3.7%	2.9%	2.6%
--- + MMF/MPA + Steroids	1.0%	0.7%	1.1%	1.4%	0.0%	0.9%	0.0%	0.0%
CyA + MMF/MPA + Steroids	20.6%	9.4%	7.6%	4.6%	9.6%	5.1%	4.4%	2.6%
Tac + MMF/MPA + Steroids	57.8%	67.4%	52.4%	47.9%	51.6%	43.1%	46.5%	49.7%
--- + OtherAntimet + Steroids	1.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
CyA + OtherAntimet + Steroids	2.9%	0.7%	1.1%	0.9%	0.4%	0.0%	0.0%	0.5%
Tac + OtherAntimet + Steroids	4.9%	4.3%	2.2%	0.5%	1.2%	1.9%	1.5%	2.6%
--- + Siro/Evero + Steroids	0.0%	0.0%	0.0%	0.5%	1.6%	0.5%	0.4%	0.0%
CyA + Siro/Evero + Steroids	0.0%	1.4%	2.2%	1.8%	1.6%	0.9%	0.7%	0.5%
Tac + Siro/Evero + Steroids	3.9%	3.6%	13.5%	13.4%	10.4%	10.2%	7.0%	5.6%
Other Regimen	1.0%	2.9%	5.4%	6.0%	5.2%	7.4%	6.6%	4.6%

Source: OPTN/SRTR Data as of May 1, 2008.

Notes:

Percentages are calculated based on the total number of patients with maintenance use at two years following transplantation. They sum to 100 percent for each column. Transplants prior to year 1998 are not reported due to insufficient reporting of immunosuppressive drug use.

---: No Calcineurin Inhibitor Use; CyA: Cyclosporine; Tac: Tacrolimus.

MMF: Mycophenolate Mofetil; MPA: Mycophenolate Sodium; Siro: Sirolimus; Evero: Everolimus; OtherAntimet: Antimetabolites excluding MMF and MPA.

"Other Regimen" includes drug combinations that are different from the listed regimens and drugs from the text field entering.